| Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models DB Kirpotin, DC Drummond, Y Shao, MR Shalaby, K Hong, UB Nielsen, ... Cancer research 66 (13), 6732-6740, 2006 | 1549 | 2006 |
| Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery JW Park, K Hong, DB Kirpotin, G Colbern, R Shalaby, J Baselga, Y Shao, ... Clinical Cancer Research 8 (4), 1172-1181, 2002 | 1103 | 2002 |
| Systems biology and combination therapy in the quest for clinical efficacy JB Fitzgerald, B Schoeberl, UB Nielsen, PK Sorger Nature chemical biology 2 (9), 458-466, 2006 | 723 | 2006 |
| Tumor targeting using anti-her2 immunoliposomes JW Park, DB Kirpotin, K Hong, R Shalaby, Y Shao, UB Nielsen, JD Marks, ... Journal of controlled release 74 (1-3), 95-113, 2001 | 551 | 2001 |
| Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data WW Chen, B Schoeberl, PJ Jasper, M Niepel, UB Nielsen, ... Molecular systems biology 5 (1), 239, 2009 | 492 | 2009 |
| Therapeutically targeting ErbB3: A key node in ligand-induced activation of the ErbB receptor–PI3K axis B Schoeberl, EA Pace, JB Fitzgerald, BD Harms, L Xu, L Nie, B Linggi, ... Science signaling 2 (77), ra31-ra31, 2009 | 444 | 2009 |
| Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 CF McDonagh, A Huhalov, BD Harms, S Adams, V Paragas, S Oyama, ... Molecular cancer therapeutics 11 (3), 582-593, 2012 | 373 | 2012 |
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation B Schoeberl, AC Faber, D Li, MC Liang, K Crosby, M Onsum, ... Cancer research 70 (6), 2485-2494, 2010 | 334 | 2010 |
| Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis UB Nielsen, DB Kirpotin, EM Pickering, K Hong, JW Park, MR Shalaby, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1591 (1-3), 109-118, 2002 | 325 | 2002 |
| Selection of tumor-specific internalizing human antibodies from phage libraries MA Poul, B Becerril, UB Nielsen, P Morisson, JD Marks Journal of molecular biology 301 (5), 1149-1161, 2000 | 322 | 2000 |
| Multiplexed sandwich assays in microarray format UB Nielsen, BH Geierstanger Journal of immunological methods 290 (1-2), 107-120, 2004 | 321 | 2004 |
| Profiling receptor tyrosine kinase activation by using Ab microarrays UB Nielsen, MH Cardone, AJ Sinskey, G MacBeath, PK Sorger Proceedings of the National Academy of Sciences 100 (16), 9330-9335, 2003 | 289 | 2003 |
| The response of human epithelial cells to TNF involves an inducible autocrine cascade KA Janes, S Gaudet, JG Albeck, UB Nielsen, DA Lauffenburger, ... Cell 124 (6), 1225-1239, 2006 | 261 | 2006 |
| Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion AV Kalra, J Kim, SG Klinz, N Paz, J Cain, DC Drummond, UB Nielsen, ... Cancer research 74 (23), 7003-7013, 2014 | 228 | 2014 |
| Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity UB Nielsen, GP Adams, LM Weiner, JD Marks Cancer research 60 (22), 6434-6440, 2000 | 206 | 2000 |
| Expression of single-chain Fv-Fc fusions in Pichia pastoris DB Powers, P Amersdorfer, MA Poul, UB Nielsen, MR Shalaby, ... Journal of immunological methods 251 (1-2), 123-135, 2001 | 186 | 2001 |
| HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity JG Reynolds, E Geretti, BS Hendriks, H Lee, SC Leonard, SG Klinz, ... Toxicology and applied pharmacology 262 (1), 1-10, 2012 | 158 | 2012 |
| Connector element for high-speed data communications MP Jensen, U Nielsen US Patent 6,464,529, 2002 | 155 | 2002 |
| MM-141, an IGF-IR–and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors JB Fitzgerald, BW Johnson, J Baum, S Adams, S Iadevaia, J Tang, ... Molecular cancer therapeutics 13 (2), 410-425, 2014 | 129 | 2014 |
| Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors DC Kirouac, JY Du, J Lahdenranta, R Overland, D Yarar, V Paragas, ... Science signaling 6 (288), ra68-ra68, 2013 | 127 | 2013 |
